Constipation Treatment Market Scope and Key Players Analysis by 2031
Constipation Treatment Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2023 | US$ 9.93 billion |
Market Size by 2031 | US$ 17.69 billion |
Global CAGR (2023 - 2031) | 6.0% |
Historical Data | 2021-2023 |
Forecast period | 2024-2031 |
Segments Covered |
By Therapeutic
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Constipation Treatment Market News and Recent Developments
The Constipation Treatment Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for constipation and strategies:
- Lupin Life, the consumer healthcare business of global pharma major, Lupin Limited launched the Softovac Liquifibre, a 100% Ayurvedic liquid laxative. With this, the company enters the Indian liquid laxative market with this innovative product that is a formulation of Isabgol fibre in liquid form and natural actives such as Sonamukhi, Harad, Mulethi, Saunf, Amaltas and Gulab Dal. (Source: Lupin, Company Website, 2023)
- Ironwood Pharmaceuticals, Inc. a GI-focused healthcare company, received U.S. Food and Drug Administration (FDA) approval for LINZESS (linaclotide) as a once-daily treatment for pediatric patients ages 6-17 years-old with functional constipation. LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population. (Source: Ironwood, Company Website, 2023)
- EA Pharma’s parent company Eisai Co., Ltd. and Mochida Pharmaceutical Co., Ltd. launched MOVICOL HD for the treatment of chronic constipation in Japan. MOVICOL HD contains the same active ingredients in double the quantity of MOVICOL LD per sachet. It increases the water retention in the intestinal tract by osmolality of its main ingredient polyethylene glycol (macrogol 4000), which increases fecal moisture, softens feces, increases fecal volume and physiologically activates the peristaltic movement of the colon to promote bowel movement. (Source: Eisai Co., Ltd., Company Website, 2022)
- Ardelyx, Inc. launched IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. It treats the abdominal pain, bloating, and discomfort, along with the constipation associated with this debilitating condition. (Source: Ardelyx, Inc., Newsletter, 2022)
Constipation Treatment Market Report Coverage and Deliverables
The “Constipation Treatment Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Market dynamics such as drivers, restraints, and key opportunities
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
- Detailed company profiles